

UroLift™ System

“Clinical application of the UroLift™ prostatic urethral lift in Spain: consensus on the treatment of lower urinary tract symptoms associated with urinary flow obstruction and secondary to benign prostatic hyperplasia (BPH)”

Fernández Arjona M, López Martín L, Herranz Fernández LM, Sinues Ojas B, Campá Bortoló JM, Extramiana Cameno J, López Alcina E, Povo Martín I, Budía Alba A, Ordaz Jurado G, Osca García JM, Perán Teruel M, Gimeno Argente V, Navarro Beltrán A, Benjam Gual J, Hernández Martínez YE, González Enguita C

Highlights from a Spanish Article

CONSENSUS Recommendations for treating patients with LUTS/BPH

The UroLift™ System is an approved technology designed to treat lower urinary tract symptoms (LUTS) secondary to BPH and is used to perform the prostatic urethral lift (PUL) procedure.

- LUTS are a frequent reason for consultation in primary care
- BPH, the leading cause of specialist consultation in urology

Both primary care physicians (PCP) and urologists can evaluate and offer PUL as an effective MIST.

Evidence-based benefits

Currently, PUL using the UroLift™ System is considered a standard of care by leading European guidelines such as:

- The European Association of Urology (EAU)
- The UK's National Institute for Health and Care Excellence (NICE)

The procedure offers rapid and significant improvement:

- International Prostate Symptom Score (IPSS)
- QoL due to immediate urethral clearance



Enlarged Prostate

An enlarged prostate can narrow or even block the urethra.



Step 1

The UroLift™ Delivery Device is placed through the obstructed urethra to access the enlarged prostate.



Step 2

Small UroLift™ implants are permanently placed to lift and hold the enlarged prostate tissue out of the way and increase the opening of the urethra. The permanent Implants are delivered through a small needle that comes out of the UroLift™ Delivery Device and into the prostate.



Step 3

The UroLift™ System procedure provides quick symptom relief by opening the obstructed urethra.

UroLift™ System

Re-treatment rate
13.6%
after 5yrs

- Implants induce tissue remodeling
- Minimal need for bladder catheterisation
- It preserves sexual function
(no de novo sustained alterations to ejaculatory or erectile function)

Benefits
over pharmacological
treatment

- Due to the mechanical approach to reducing urethral obstruction, PUL does not present systemic effects.
- Adverse reactions are common with alpha-blockers and 5ARI treatments
- PUL procedure avoids the problems of adherence to treatment as described in the literature for medical therapy

Candidates for UroLift™ System treatment in Spain

Inclusion Criteria

- Patients ≥ 45 years (> 50 as EU Instructions For Use)
- Patients with prostate size ≤ 100
- Presence of obstructive median lobe: Intravesical prostatic protrusion limit < 1.5 cm (measured by ultrasound)
- Presence of a progressive reduction in peak flow on flowmetry in the previous year, with a final value < 15 ml/s
- Patients with an IPSS > 7
- Patients with no clinical suspicion of prostate cancer
- Alternative to systemic treatment in patients who are refractory or non-adherent to pharmacological therapy
- Patients who wish to preserve erectile and ejaculatory function

Exclusion Criteria

- Elevated bladder neck
- Previous prostate surgery
- Urethral structure
- Active Urinary tract infection
- Allergy of hypersensitivity to the components

Safety Information

Indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 50 years or older. As with any medical procedure, individual results may vary. Most common side effects are temporary and include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. (Roehrborn, et al. J Urol 2013) Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Consult the Instructions for Use (IFU) for more information.

Except as otherwise noted, Teleflex did not sponsor, pay for, or independently verify the results of the work summarized here and therefore is not responsible for the methodology utilized or the results obtained. Teleflex has made all efforts to summarize the work accurately but cannot guarantee the accuracy or completeness of the summary as it is based on the original paper. In the event an inaccuracy arises, please inform Teleflex so that it can be corrected.

Ref. Original Article:

Fernández Arjona M, López Martín L, Herranz Fernández LM, et al. Clinical application of the UroLift™ prostatic urethral lift in Spain: consensus on the treatment of lower urinary tract symptoms associated with urinary flow obstruction and secondary to benign prostatic hyperplasia (BPH). Actas Urol Esp (Engl Ed). 2024;48(10):732-738. doi:10.1016/j.acuroe.2024.09.004

Teleflex, the Teleflex logo, and UroLift are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are the property of their respective owners. Information in this document is not a substitute for the product Instructions for Use. Please contact your local representative. Revised: 08/2025. ©2025 Teleflex Incorporated. All rights reserved.

MCI-2025-0591-EN · Rev 0 · 08/2025